Cytosorbents (CTSO) Free Cash Flow Growth (3y) (2013 - 2026)
Cytosorbents (CTSO) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | 41.96% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 25.48% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 0.05% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 35.42% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 250.09% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | 12.01% |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 35.65% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 20.87% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 9.23% |
| 10 | Cytosorbents | 23.26 Mn | 18.85 Mn | 7.05 Mn | 55.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 55.39% |
| Mar 31, 2026 | 27.73% |
| Dec 31, 2025 | -212.13% |
| Sep 30, 2025 | 40.60% |
| Jun 30, 2025 | 41.08% |
| Mar 31, 2025 | 26.77% |
| Dec 31, 2024 | 38.41% |
| Sep 30, 2024 | 3.57% |
| Jun 30, 2024 | -19.43% |
| Mar 31, 2024 | -20.69% |
| Dec 31, 2023 | -78.57% |
| Sep 30, 2023 | -14.00% |
| Jun 30, 2023 | -78.98% |
| Mar 31, 2023 | 3.37% |
| Dec 31, 2022 | 26.84% |
| Sep 30, 2022 | -32.39% |
| Jun 30, 2022 | -31.46% |
| Mar 31, 2022 | -24.91% |
| Dec 31, 2021 | -46.86% |
| Sep 30, 2021 | -3.08% |